These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9398110)

  • 1. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction.
    Oshima S; Ogawa H; Mizuno Y; Yamashita S; Noda K; Saito T; Sumida H; Suefuji H; Kaikita K; Soejima H; Yasue H
    Am Heart J; 1997 Nov; 134(5 Pt 1):961-6. PubMed ID: 9398110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction.
    Soejima H; Ogawa H; Yasue H; Suefuji H; Kaikita K; Nishiyama K
    Clin Cardiol; 1997 May; 20(5):441-5. PubMed ID: 9134274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction.
    Mizuno Y; Yasue H; Oshima S; Yoshimura M; Ogawa H; Morita E; Saito T; Yamashita S; Noda K; Sumida H; Motoyama T; Soejima H; Nakao K
    J Card Fail; 1997 Dec; 3(4):287-93. PubMed ID: 9547443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
    Hosoya K; Ishimitsu T
    Cardiovasc Drug Rev; 2002; 20(2):93-110. PubMed ID: 12177688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
    Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
    Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
    Pedersen OD; Gram J; Jeunemaitre X; Billaud E; Jespersen J
    Coron Artery Dis; 1997 May; 8(5):283-91. PubMed ID: 9285181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency.
    Yoshitomi Y; Kojima S; Yano M; Sugi T; Matsumoto Y; Kuramochi M
    Am Heart J; 2000 Dec; 140(6):E27. PubMed ID: 11100000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril.
    van Veldhuisen DJ; Genth-Zotz S; Brouwer J; Boomsma F; Netzer T; Man In 'T Veld AJ; Pinto YM; Lie KI; Crijns HJ
    J Am Coll Cardiol; 1998 Dec; 32(7):1811-8. PubMed ID: 9857856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
    Yajima K; Shimada A; Hirose H; Oikawa Y; Yamada S; Meguro S; Irie J; Irie S
    Clin Drug Investig; 2009; 29(12):811-9. PubMed ID: 19888787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imidapril, an angiotensin-converting enzyme inhibitor, inhibits thrombosis via reduction in aortic plasminogen activator inhibitor type-1 levels in spontaneously hypertensive rats.
    Mitsui T; Chishima S; Odawara A; Ohtani A
    Biol Pharm Bull; 1999 Aug; 22(8):863-5. PubMed ID: 10480327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidapril and enalapril similarly inhibit plasma matrix metalloproteinase activities and attenuate left ventricular remodeling in patients with acute myocardial infarction.
    Yokota T; Tomita H; Mori Y; Kudo T; Hiraga H; Suto N; Higuma T; Abe N; Hanada H; Osanai T; Okumura K
    J Cardiovasc Pharmacol; 2014 Jun; 63(6):528-32. PubMed ID: 24709636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis.
    Katoh M; Egashira K; Mitsui T; Chishima S; Takeshita A; Narita H
    J Mol Cell Cardiol; 2000 Jan; 32(1):73-83. PubMed ID: 10652192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.
    Vaughan DE; Rouleau JL; Ridker PM; Arnold JM; Menapace FJ; Pfeffer MA
    Circulation; 1997 Jul; 96(2):442-7. PubMed ID: 9244210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction.
    Moriyama Y; Ogawa H; Oshima S; Takazoe K; Honda Y; Hirashima O; Arai H; Sakamoto T; Sumida H; Suefuji H; Kaikita K; Yasue H
    Jpn Circ J; 1997 Apr; 61(4):308-14. PubMed ID: 9152782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Force-length relationship in dogs as a measure of protective effect of imidapril on regional myocardial ischemia and reperfusion injury.
    Hosoya K; Takeda K; Nishikimi T; Ishimitsu T; Matsuoka H
    Eur J Pharmacol; 2000 Feb; 390(1-2):157-66. PubMed ID: 10708719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
    Voors AA; de Kam PJ; van den Berg MP; Borghi C; Hochman JS; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):119-24. PubMed ID: 16025230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
    Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
    Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
    Higashi Y; Sasaki S; Nakagawa K; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2001 Mar; 37(3):863-70. PubMed ID: 11693763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidapril in heart failure.
    Dolezal T
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):146-54. PubMed ID: 17094051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.